TSE:LABS

MediPharm Labs Competitors

C$0.47
-0.01 (-2.08 %)
(As of 04/16/2021 05:41 PM ET)
Add
Compare
Today's Range
C$0.46
Now: C$0.47
C$0.48
50-Day Range
C$0.46
MA: C$0.51
C$0.74
52-Week Range
C$0.45
Now: C$0.47
C$2.25
Volume1.09 million shs
Average Volume2.66 million shs
Market CapitalizationC$121.24 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

MediPharm Labs (TSE:LABS) Vs. RIV, WLLW, KHRN, DN, META, and NRTH

Should you be buying LABS stock or one of its competitors? Companies in the industry of "drug manufacturers—specialty & generic" are considered alternatives and competitors to MediPharm Labs, including RIV Capital (RIV), Willow Biosciences Inc. (WLLW.TO) (WLLW), Khiron Life Sciences (KHRN), Delta 9 Cannabis (DN), Meta Growth (META), and 48North Cannabis (NRTH).

MediPharm Labs (TSE:LABS) and RIV Capital (TSE:RIV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for MediPharm Labs and RIV Capital, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs02023.00
RIV Capital01002.00

MediPharm Labs presently has a consensus target price of C$1.53, suggesting a potential upside of 225.53%. RIV Capital has a consensus target price of C$4.00, suggesting a potential upside of 90.48%. Given MediPharm Labs' stronger consensus rating and higher possible upside, equities analysts plainly believe MediPharm Labs is more favorable than RIV Capital.

Profitability

This table compares MediPharm Labs and RIV Capital's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm LabsN/AN/AN/A
RIV CapitalN/AN/AN/A

Earnings & Valuation

This table compares MediPharm Labs and RIV Capital's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$36.01 million3.37C$-123,815,040.00C($0.48)-0.98
RIV CapitalC$15.44 million19.03C$-106,223,568.00C($0.76)-2.77

RIV Capital has lower revenue, but higher earnings than MediPharm Labs. RIV Capital is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Summary

MediPharm Labs beats RIV Capital on 6 of the 8 factors compared between the two stocks.

MediPharm Labs (TSE:LABS) and Willow Biosciences Inc. (WLLW.TO) (TSE:WLLW) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Earnings and Valuation

This table compares MediPharm Labs and Willow Biosciences Inc. (WLLW.TO)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$36.01 million3.37C$-123,815,040.00C($0.48)-0.98
Willow Biosciences Inc. (WLLW.TO)C$10,000.0016,271.38C$-51,032,952.00C($0.41)-3.19

Willow Biosciences Inc. (WLLW.TO) has lower revenue, but higher earnings than MediPharm Labs. Willow Biosciences Inc. (WLLW.TO) is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MediPharm Labs and Willow Biosciences Inc. (WLLW.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm LabsN/AN/AN/A
Willow Biosciences Inc. (WLLW.TO)N/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations for MediPharm Labs and Willow Biosciences Inc. (WLLW.TO), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs02023.00
Willow Biosciences Inc. (WLLW.TO)0000N/A

MediPharm Labs currently has a consensus target price of C$1.53, suggesting a potential upside of 225.53%. Willow Biosciences Inc. (WLLW.TO) has a consensus target price of C$2.25, suggesting a potential upside of 70.45%. Given MediPharm Labs' higher possible upside, research analysts plainly believe MediPharm Labs is more favorable than Willow Biosciences Inc. (WLLW.TO).

Summary

MediPharm Labs beats Willow Biosciences Inc. (WLLW.TO) on 4 of the 7 factors compared between the two stocks.

MediPharm Labs (TSE:LABS) and Khiron Life Sciences (CVE:KHRN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings.

Profitability

This table compares MediPharm Labs and Khiron Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm LabsN/AN/AN/A
Khiron Life SciencesN/AN/AN/A

Analyst Ratings

This is a breakdown of current recommendations and price targets for MediPharm Labs and Khiron Life Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs02023.00
Khiron Life Sciences0000N/A

MediPharm Labs currently has a consensus target price of C$1.53, indicating a potential upside of 225.53%. Khiron Life Sciences has a consensus target price of C$1.20, indicating a potential upside of 135.29%. Given MediPharm Labs' higher possible upside, research analysts plainly believe MediPharm Labs is more favorable than Khiron Life Sciences.

Valuation and Earnings

This table compares MediPharm Labs and Khiron Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$36.01 million3.37C$-123,815,040.00C($0.48)-0.98
Khiron Life SciencesC$8.01 million9.56C$-39,493,921.00C($0.26)-1.94

Khiron Life Sciences has lower revenue, but higher earnings than MediPharm Labs. Khiron Life Sciences is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Summary

MediPharm Labs beats Khiron Life Sciences on 4 of the 7 factors compared between the two stocks.

Delta 9 Cannabis (TSE:DN) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Delta 9 Cannabis and MediPharm Labs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delta 9 CannabisC$52.05 million1.14C$-7,346,808.00C($0.07)-8.06
MediPharm LabsC$36.01 million3.37C$-123,815,040.00C($0.48)-0.98

Delta 9 Cannabis has higher revenue and earnings than MediPharm Labs. Delta 9 Cannabis is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Delta 9 Cannabis and MediPharm Labs, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Delta 9 Cannabis00014.00
MediPharm Labs02023.00

Delta 9 Cannabis currently has a consensus target price of C$1.10, indicating a potential upside of 89.66%. MediPharm Labs has a consensus target price of C$1.53, indicating a potential upside of 225.53%. Given MediPharm Labs' higher probable upside, analysts clearly believe MediPharm Labs is more favorable than Delta 9 Cannabis.

Profitability

This table compares Delta 9 Cannabis and MediPharm Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Delta 9 CannabisN/AN/AN/A
MediPharm LabsN/AN/AN/A

MediPharm Labs (TSE:LABS) and Meta Growth (CVE:META) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Valuation and Earnings

This table compares MediPharm Labs and Meta Growth's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$36.01 million3.37C$-123,815,040.00C($0.48)-0.98
Meta GrowthC$60.96 million0.54C$-50,412,840.00C($0.21)-0.66

Meta Growth has higher revenue and earnings than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than Meta Growth, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MediPharm Labs and Meta Growth's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm LabsN/AN/AN/A
Meta GrowthN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for MediPharm Labs and Meta Growth, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs02023.00
Meta Growth0000N/A

MediPharm Labs currently has a consensus target price of C$1.53, suggesting a potential upside of 225.53%. Given MediPharm Labs' higher possible upside, equities research analysts clearly believe MediPharm Labs is more favorable than Meta Growth.

Summary

Meta Growth beats MediPharm Labs on 4 of the 7 factors compared between the two stocks.

MediPharm Labs (TSE:LABS) and 48North Cannabis (CVE:NRTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Profitability

This table compares MediPharm Labs and 48North Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MediPharm LabsN/AN/AN/A
48North CannabisN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for MediPharm Labs and 48North Cannabis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MediPharm Labs02023.00
48North Cannabis0000N/A

MediPharm Labs currently has a consensus target price of C$1.53, indicating a potential upside of 225.53%. Given MediPharm Labs' higher probable upside, analysts clearly believe MediPharm Labs is more favorable than 48North Cannabis.

Valuation and Earnings

This table compares MediPharm Labs and 48North Cannabis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MediPharm LabsC$36.01 million3.37C$-123,815,040.00C($0.48)-0.98
48North CannabisC$17.36 million1.84C$-52,460,873.00C($0.26)-0.61

48North Cannabis has lower revenue, but higher earnings than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than 48North Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

MediPharm Labs beats 48North Cannabis on 4 of the 7 factors compared between the two stocks.


MediPharm Labs Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RIV
RIV Capital
0.8$2.10-2.4%C$293.90 millionC$15.44 million-2.77
WLLW
Willow Biosciences Inc. (WLLW.TO)
1.1$1.32-0.0%C$162.10 millionC$10,000.00-3.19Gap Up
KHRN
Khiron Life Sciences
0.9$0.51-2.0%C$67.34 millionC$8.01 million-1.94Gap Down
DN
Delta 9 Cannabis
1.4$0.58-0.0%C$59.18 millionC$52.05 million-8.06
META
Meta Growth
0.8$0.14-0.0%C$36.69 millionC$60.96 million-0.66Gap Up
NRTH
48North Cannabis
0.7$0.16-6.3%C$36.44 millionC$17.36 million-0.61
CSI
(CSI)
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
BAMM
28896
0.5N/AN/A$0.00N/A0.00High Trading Volume
ATT
Abattis Bioceuticals
0.5N/AN/AC$0.00N/A0.00Gap Down
AGRA
Agraflora Organics International
1.4N/AN/A$0.00N/A0.00High Trading Volume
GRIN
Grindrod Shipping
1.7N/AN/A$0.00N/A0.00High Trading Volume
IMCC
IM Cannabis
0.0N/AN/A$0.00N/A0.00High Trading Volume
PULL
Mind Cure Health
1.7N/AN/A$0.00N/A0.00High Trading Volume
SPR
Spirit AeroSystems
0.5N/AN/A$0.00N/A0.00High Trading Volume
BUZZ
VanEck Vectors Social Sentiment ETF
1.0N/AN/A$0.00N/A0.00High Trading Volume
VIDA
Vidaroo
0.5N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.